Skip to main content
. 2019 Sep 18;20(18):4624. doi: 10.3390/ijms20184624

Figure 6.

Figure 6

Emerging predictive biomarker of response to immune checkpoint inhibitor. The programmed cell-death 1 and its ligand (PD-1/PD-L1) are tumor escape factors used widely as predictive biomarkers for patient’s response to immunotherapy. Other suggestive biomarkers include genomic, tumor-escape, immune-microenvironment and host factors. These factors include TMB (tumor mutation burden), MMrd (mismatch repair deficiency), VI (oncogenic viral infection), ODM (oncogenic driver mutation), TIL (tumor infiltrating lymphocyte), ISF (Immune suppressor factor) and tumor immune phenotype (TIP).